Leonie Schwartze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leonie Schwartze has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Christian Zoschke
Institute of Pharmacy (Pharmacology & Toxicology), Freie Universität Berlin, Königin-Luise-Str. 2+4, 14195 Berlin, Germany
3 shared publications - Eckart Rühl
Freie Universität Berlin, Physikalische Chemie, Institut für Chemie und Biochemie, Arnimallee 22, 14195 Berlin, Germany
2 shared publications - Bernhard Wuest
Agilent Technologies GmbH, Hewlett-Packard-Str. 8, 76337 Waldbronn, Germany
1 shared publication - Gregor Germer
Freie Universität Berlin, Institut für Chemie und Biochemie, 14195 Berlin, Germany
1 shared publication Isabel Ruehl
Physical Chemistry, Freie Universität Berlin, Arnimallee 22, 14195 Berlin, Germany
1 shared publication- Jan Felix Joseph
Core Facility BioSupraMol PharmaMS, Institute of Pharmacy, Freie Universitaet Berlin, Koenigin-Luise-Straße 2+4, 14195 Berlin, Germany
1 shared publication
Latest Publications
- 3 June 2025
- Published by Walter de Gruyter GmbH in Zeitschrift für Physikalische Chemie
Cetuximab-induced changes to tumor oral mucosa models probed by stimulated Raman spectromicroscopy
Spontaneous and stimulated Raman spectromicroscopy is reported to investigate the cetuximab uptake in a head and neck cancer oral mucosa model and to unravel drug induced cellular changes in a label-free approach. Specifically, stimulated Raman spectromicroscopy is sensitive to probe the spatial distribution of cetuximab as well as drug-induced changes in spatial distributions of proteins, lipids, and DNA. The distinct vibrational bands of the CH3-stretch of proteins and the CH2-stretch of lipids indicate drug-induced cellular modifications, which are retrieved by a linear decomposition algorithm. Topical and systemic drug application pathways were studied, indicating an increased total protein content by a factor of ∼2 and ∼1.5, respectively, compared to an untreated control. Protein and lipid profiles as well as drug distributions were monitored, demonstrating the potential of Raman-based spectromicroscopy for probing changes induced by cetuixmab. Following cetuximab therapy, the relative protein content increases, while the lipid concentration decreases. Accumulation of lipid droplet-like structures near tumor cell membranes with less nucleic acid-like material in treated tumor oral mucosa models was also observed. The results are compared to related spectromicroscopy approaches involving fluorescence labels and label-free photothermal expansion indicating that stimulated Raman spectromicroscopy reveals sensitively biological post-treatment effects, while no reduction in tumor size occurs.
- 3 June 2025
- Published by Walter de Gruyter GmbH in Zeitschrift für Physikalische Chemie
Cetuximab-induced changes to tumor oral mucosa models probed by stimulated Raman spectromicroscopy
Spontaneous and stimulated Raman spectromicroscopy is reported to investigate the cetuximab uptake in a head and neck cancer oral mucosa model and to unravel drug induced cellular changes in a label-free approach. Specifically, stimulated Raman spectromicroscopy is sensitive to probe the spatial distribution of cetuximab as well as drug-induced changes in spatial distributions of proteins, lipids, and DNA. The distinct vibrational bands of the CH3-stretch of proteins and the CH2-stretch of lipids indicate drug-induced cellular modifications, which are retrieved by a linear decomposition algorithm. Topical and systemic drug application pathways were studied, indicating an increased total protein content by a factor of ∼2 and ∼1.5, respectively, compared to an untreated control. Protein and lipid profiles as well as drug distributions were monitored, demonstrating the potential of Raman-based spectromicroscopy for probing changes induced by cetuixmab. Following cetuximab therapy, the relative protein content increases, while the lipid concentration decreases. Accumulation of lipid droplet-like structures near tumor cell membranes with less nucleic acid-like material in treated tumor oral mucosa models was also observed. The results are compared to related spectromicroscopy approaches involving fluorescence labels and label-free photothermal expansion indicating that stimulated Raman spectromicroscopy reveals sensitively biological post-treatment effects, while no reduction in tumor size occurs.
- Open Access
- 23 February 2024
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 149 (7) , 2122-2130
Label-free mapping of cetuximab in multi-layered tumor oral mucosa models by atomic force-microscopy-based infrared spectroscopy
Sensitive mapping of drugs and drug delivery systems is pivotal for the understanding and improvement of treatment options. Since labeling alters the physicochemical and potentially the pharmacological properties of the molecule of interest, its label-free detection by photothermal expansion is investigated. We report on a proof-of-concept study to map the cetuximab distribution by atomic-force microscopy-based infrared spectroscopy (AFM-IR). The monoclonal antibody cetuximab was applied to a human tumor oral mucosa model, consisting of a tumor epithelium on a lamina propria equivalent. Hyperspectral imaging in the wavenumber regime between 903 cm-1 and 1312 cm-1 and a probing distance between the data points down to 10 x 10 nm are used for determining the local drug distribution. The local distinction of cetuximab from the tissue background is gained by linear combination modeling making use of reference spectra of the drug and untreated models. The results from this approach are compared to principal component analyses, yielding comparable results. Even single molecule detection appears feasible. The results indicate that cetuximab penetrates the cytosol of tumor cells but does not bind to structures in the cell membrane. In conclusion, AFM-IR mapping of cetuximab proved to sensitively determine drug concentrations at an unprecedented spatial resolution without the need for drug labeling.
- 23 February 2024
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 149 (7) , 2122-2130
Open AccessLabel-free mapping of cetuximab in multi-layered tumor oral mucosa models by atomic force-microscopy-based infrared spectroscopy
Sensitive mapping of drugs and drug delivery systems is pivotal for the understanding and improvement of treatment options. Since labeling alters the physicochemical and potentially the pharmacological properties of the molecule of interest, its label-free detection by photothermal expansion is investigated. We report on a proof-of-concept study to map the cetuximab distribution by atomic-force microscopy-based infrared spectroscopy (AFM-IR). The monoclonal antibody cetuximab was applied to a human tumor oral mucosa model, consisting of a tumor epithelium on a lamina propria equivalent. Hyperspectral imaging in the wavenumber regime between 903 cm-1 and 1312 cm-1 and a probing distance between the data points down to 10 x 10 nm are used for determining the local drug distribution. The local distinction of cetuximab from the tissue background is gained by linear combination modeling making use of reference spectra of the drug and untreated models. The results from this approach are compared to principal component analyses, yielding comparable results. Even single molecule detection appears feasible. The results indicate that cetuximab penetrates the cytosol of tumor cells but does not bind to structures in the cell membrane. In conclusion, AFM-IR mapping of cetuximab proved to sensitively determine drug concentrations at an unprecedented spatial resolution without the need for drug labeling.
- Open Access
- 30 April 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (5) , 413
Automated Real-Time Tumor Pharmacokinetic Profiling in 3D Models: A Novel Approach for Personalized Medicine
Cancer treatment often lacks individual dose adaptation, contributing to insufficient efficacy and severe side effects. Thus, personalized approaches are highly desired. Although various analytical techniques are established to determine drug levels in preclinical models, they are limited in the automated real-time acquisition of pharmacokinetic profiles. Therefore, an online UHPLC-MS/MS system for quantitation of drug concentrations within 3D tumor oral mucosa models was generated. The integration of sampling ports into the 3D tumor models and their culture inside the autosampler allowed for real-time pharmacokinetic profiling without additional sample preparation. Docetaxel quantitation was validated according to EMA guidelines. The tumor models recapitulated the morphology of head-and-neck cancer and the dose-dependent tumor reduction following docetaxel treatment. The administration of four different docetaxel concentrations resulted in comparable courses of concentration versus time curves for 96 h. In conclusion, this proof-of-concept study demonstrated the feasibility of real-time monitoring of drug levels in 3D tumor models without any sample preparation. The inclusion of patient-derived tumor cells into our models may further optimize the pharmacotherapy of cancer patients by efficiently delivering personalized data of the target tissue.
- 30 April 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (5) , 413
Open AccessAutomated Real-Time Tumor Pharmacokinetic Profiling in 3D Models: A Novel Approach for Personalized Medicine
Cancer treatment often lacks individual dose adaptation, contributing to insufficient efficacy and severe side effects. Thus, personalized approaches are highly desired. Although various analytical techniques are established to determine drug levels in preclinical models, they are limited in the automated real-time acquisition of pharmacokinetic profiles. Therefore, an online UHPLC-MS/MS system for quantitation of drug concentrations within 3D tumor oral mucosa models was generated. The integration of sampling ports into the 3D tumor models and their culture inside the autosampler allowed for real-time pharmacokinetic profiling without additional sample preparation. Docetaxel quantitation was validated according to EMA guidelines. The tumor models recapitulated the morphology of head-and-neck cancer and the dose-dependent tumor reduction following docetaxel treatment. The administration of four different docetaxel concentrations resulted in comparable courses of concentration versus time curves for 96 h. In conclusion, this proof-of-concept study demonstrated the feasibility of real-time monitoring of drug levels in 3D tumor models without any sample preparation. The inclusion of patient-derived tumor cells into our models may further optimize the pharmacotherapy of cancer patients by efficiently delivering personalized data of the target tissue.